KOLOA, Hawaii — Surgeons can ease the burden of managing inflammation in their postoperative cataract patients by using FDA-approved sustained release steroids, Cynthia A. Matossian, MD, FACS, said at Hawaiian Eye 2020.
Dexycu (dexamethasone intraocular suspension 9%, EyePoint Pharmaceuticals) and Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) do not carry the safety concerns associated with non-FDA-approved compounded intracameral products used in cataract surgery, she said in a debate with John P. Berdahl, MD.
Matossian cited the FDA’s position that
Uncategorized